MesoTV | NOW ENROLLING: Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Dr. Aaron Mansfield of the Mayo Clinic joins us to discuss a new, now enrolling, clinical trial for peritoneal mesothelioma that randomizes patients into two arms: an arm that receives chemotherapy + bevacizumab, and an arm that receives chemotherapy, bevacizumab and immunotherapy.

About peritoneal mesothelioma

Peritoneal mesothelioma, the rarer of the two most frequently occurring types of mesothelioma, is a cancer affecting the abdominal lining, also known as peritoneum.

Currently, there is no standard of care specific to peritoneal mesothelioma, though patients are often treated with the combination of platinum and pemetrexed chemotherapy (also known as cisplatin or carboplatin, and Alimta). HIPEC, short for Hyperthermic Intraperitoneal Chemotherapy, is another frequently used treatment option for peritoneal mesothelioma.

About the clinical trial

This clinical trial seeks to evaluate the response rate in patients with peritoneal mesothelioma after treatment with immunotherapy plus the usual treatment of chemotherapy and an anti-angiogenesis agent. The trial will compare two arms of the study. The only difference between the two arms is the addition or subtraction of atezolizumab, a PD-L1 immunotherapy drug.

Our Sponsors

MesoTV is a program by the Mesothelioma Applied Research Foundation. This program is made possible by our generous sponsors: Belluck & Fox; Maune Raichle Hartley French & Mudd, LLC (MRHFM); Bristol Myers Squibb; AstraZeneca, & TCR2.

Search our previous episodes for topics/speakers of interest to you at www.curemeso.org/mesotv.